Comprehensive Head-to-Toe Assessment

Hello, my name is [Student Name]. It is a test that involves a body check-up whose findings are an elaborate and methodical report of the overall health status of a patient. It starts with inspection and palpation and moves on to the evaluation of each of the body systems, and does not miss out on anything. The approach helps to detect the subtle variations in time, encourages a holistic understanding, and enables an early intervention. Ultimately, this is an assessment that concerns competent individualized care planning.

Conducts Accurate Patient Assessment

Ivy Jackson is a 61 year old lady who complains of feeling tired all the time, down and demotivated after the break-up of her 38 year old marriage. Careful analysis shows that she is experiencing the symptoms of major depressive disorder and they have an emotional, psychological and physical pattern. Since her husband left, she has had insomnia, unintentional weight loss, deficit of pleasure in activities, and increased anxiety (Bains & Abdijadid, 2025). She has a very pertinent medical history of hypertension and a history of having previously suffered depression. The evaluation has covered her psychosocial history, recent stressful events, support, recent and past drug abuse, and mental status assessment, which revealed a radiating depression symptom that should be controlled through medication as well as psychotherapy.

A complete thyroid panel and vitamin D were also tested and were all within the normal range to rule out any biological cause of depression. At this point, Ivy was found to have a severe depressive disorder and she was prescribed with the use of escitalopram, a selective serotonin reuptake inhibitor. The effects desired, pharmacology and side effects of the drug were explained to her (Landy et al., 2025). Ivy did not report any considerable improvement in mood after two weeks of treatment, but she reported that she slept better with melatonin and felt slightly more active in life, which is early response to medication. Although she did not make any progress of starting individual therapy, she demonstrated some progress by taking meditation classes with her daughter, which is a slow but positive behavior change. This is an indication that compliance should be strengthened and psychoeducation and support should be offered on a regular basis.

To develop an effective and personalized plan of care, nurses will have to continue monitoring the symptoms in Ivy, improve therapeutic relationships, and promote treatment adherence. Other interventions such as cognitive behavioral therapy (CBT) or interpersonal therapy (IPT) can assist in overcoming the unresolved grief in Ivy, interpersonal tensions, and the cognitive distortions, which are to be encouraged (Srivastava et al., 2024). The background on her past and current emotional pain, and the support system in the family can provide us with the information that we need to come up with interventions that would lead to long-term recovery and prevent future relapses.

Explains Diagnosis and Findings

In our physical examination, I observed that you move and speak slowly, and we call this psychomotor retardation. You have also lost about ten pounds in the past several weeks without even making any effort, and you have told me that you are waking up a few times in the night, and you are unable to fall asleep again. Your expression was rather dull when we evaluated it, and you have stated that you feel down on most days and have complained of constant lack of energy and motivation. All these are strong indicators because they are signs of the way people act, their appetites and sleeping problems.

We may compare our results with the diagnostic criteria of MDD by adding what we have observed, your slowness in movements, unwilling weight loss and disturbed sleep to what you have reported, that is, constant sadness, lack of interest in activities and exhaustion. In other words, we are attempting to identify a mix of symptoms, which last at least two weeks, and significantly impair a person to live normally (Bains & Abdijadid, 2025). We also exclude other health conditions that can otherwise manifest as depression through the use of your regular thyroid and vitamin D. This is a good step since it will ensure that we are certain that your symptoms are not caused by some other possible underlying physical complications, and it is something that will help us direct our treatment effort towards the depression.

When I present these findings to you, I would want you to realize that you are suffering from a well-known medical condition, and it is not your fault. I describe why the depressed person has slowed movements and sleeping problems because the brain chemicals, such as serotonin and norepinephrine, that keep people in a good mood and energetic are unbalanced (Cui et al., 2024). Your weight varies in relation to not only the changes in your appetite but also how your body copes with energy when it responds to stress. Interpretation all observations in the context of the changes in the body chemistry and brain functioning, not your weakness, provides you with the right context, which makes you feel empowered to contribute to your treatment plan, as well as being precisely sure what we are working on together.

Discusses Pharmacological Treatment Options

The most widespread first-line pharmacotherapy of MDD is based on SSRIs, in particular, citalopram, sertraline, and fluoxetine, and SNRIs, i.e., venlafaxine or duloxetine. Bupropion or mirtazapine can be used in older adults with fatigue or sleep disturbance as the primary problem. All these agents have their effects by increasing monoamine neurotransmission; hence, they are effective in stabilizing mood and regulating energy levels in the long run (weeks) (Kukucka et al., 2024). Monotherapy is not deemed adequate, so it can be complemented with a low dose of atypical antipsychotics, lithium, or regulation. The best current practices in treatment selection should be the initiation of low-dose treatment in elderly patients and monitoring efficacy and tolerability during acute treatment, continuation and maintenance. 

The pharmacologic plan is based on the information about Ivy and her comorbid hypertension that is controlled by lisinopril and hydrochlorothiazide, her age and the history of discontinuation syndrome with venlafaxine. Cardiovascular interactions of SSRIs are not many, but they might lead to hyponatremia, in particular, in combination with diuretics; her sodium level must be monitored regularly. Escitalopram also interacts with the cytochrome P450, which is taken into account when considering its safety in the context of her current regimen, unlike SNRIs, which can increase blood pressure and, therefore, their use should be avoided (Chu & Wadhwa, 2025).

Her effective toleration of melatonin as a hypnotic agent implies complementary non-pharmacologic interventions, but a new agent should be cross-referenced to prevent drug-drug interactions and modified to renal and hepatic conditions. Ivy needs to be given the right directions regarding the time frames and side effects that she should anticipate when taking or adjusting antidepressants. The most frequent side effects in the early stages include nausea, vomiting, diarrhea, headache, insomnia or somnolence, and sexual dysfunction, and they disappear after four to six weeks (Edinoff et al., 2022). To reduce the risk of serotonin syndrome, she is not expected to consume alcohol and non-prescription medicines containing dextromethorphan or St. John’s Wort. Orthostatic dizziness may also occur, and this is why she should not rise suddenly after sitting. It is necessary to emphasize adherence even though the benefits might be realized in the long run in order to maximize the outcomes. We can jointly draw up a treatment plan by balancing the benefits of each medication on mood and functioning against the side-effect profile, and her history of health.

Describes Disease Pathophysiology Impact

In MDD, the changes begin in the deepest structures of the brain where neurotransmitters, which are mainly serotonin, norepinephrine and dopamine, help to regulate moods, energy and motivation. Depression interferes with the equilibrium and signaling of the said chemicals, and the imbalance is accompanied by the hyperactivity of the stress-response system (the hypothalamic-pituitary-adrenal axis), which floods the body with cortisol (Ernstmeyer & Christman, 2022). Not only will such changes influence your thoughts, but they will also impact the autonomic nervous system (heart rate and digestion of food), the endocrine system (release of hormones) and even the immune system, which is why you may become more tired or physically achy.

Unless depression is treated, you may notice that your mood will become progressively worse, and that you will feel increasingly fatigued and experience difficulties with concentration. On the physical side, the sustained high cortisol can lead to sleeping problems, either insomnia or sleeping too much, and can affect your appetite and weight (Xu et al., 2022). Emotionally, you can get irritable or disconnected with things you liked. This sense of consistently being in low gear will not only make day to day tasks to be overwhelming but over time it can also make someone feel anxious and hopeless.

These inward changes are visible and explicable. You may talk slower, be unable to find a word, or pause between the sentences. It would make your body heavy, stiff and it would take you longer time to move and to be less coordinated. You may be less interested in social activities, miss plans or have difficulty in rising in the morning. There is also a possibility to experience headaches, stomach aches or muscle aches with no apparent medical explanation (National Institute of Mental Health, 2024). Understanding that these effects are normal response of the body to alterations in chemicals and hormones rather than a weakness can help you know when you should seek help and encourage you to stick with treatment.

Care Priorities

The most significant one is to make Ms. Jackson safe and stable. This includes regular screening of suicide risk and development of a safety plan with the collaboration (APA practice guidelines) (Horowitz et al., 2023). Second, optimizing the pharmacotherapy, including assessing the efficacy and tolerability of escitalopram, early side effects, such as gastrointestinal upset, insomnia, or hyponatremia, and increasing or switching the dose or considering augmentation at week 6 in case of a lack of improvement in mood (Parish et al., 2023).

Third, addressing sleep disturbance and energy deficits through adjunctive nonpharmacologic interventions (e.g., sleep hygiene, structured activity scheduling) as well as her meditation practice. Finally, to alleviate cognitive distortions and interpersonal stressors as a result of her divorce, it is possible to facilitate evidence-based psychotherapy (CBT or IPT) (Srivastava et al., 2024).

• Integration of Assessment, Pharmacology, and Pathophysiology

The slowing of the psychomotor activity, loss of weight, and insomnia experienced by Ms. Jackson are all symptoms of the monoamine dysregulation and hyperactivity of the HPA-axis that is symptomatic of major depression disorders. By assigning these effects to her past, hypertension on hydrochlorothiazide and lisinopril, and previous venlafaxine discontinuation, we had put a value on an SSRI that has a favourable cardiovascular and metabolic safety profile. The low P450 interaction of escitalopram decreases the chances of adverse drug-drug interactions and diuretic-induced hyponatremia (Chu & Wadhwa, 2025). Close monitoring of her symptom patterns and adverse effects is the best practice in SSRI management, given that improvement of symptoms through normalization of neurotransmitters may take up to four to six weeks.

• Evidence-Based Support

These priorities are also endorsed by the APA recommendations on MDD, in which the emphasis is placed on the early safety assessment and measurement-based care as a tool for managing treatment adjustments. The American College of Physicians suggested that SSRIs be considered the first-line drug in older adults due to their safety (Karrouri et al., 2021). The suggestions of Bartova et al. (2021) supported the combination of pharmacotherapy and structured psychotherapy in order to reduce the likelihood of relapse and improve functional recovery. Our care plan is aligned with the best current practices since it combines the clinical profile of Ms. Jackson, her drug history and her neurobiological processes to maximize outcomes and future well-being.

Conclusion

Major depressive disorder is the condition of Ms. Jackson due to persistent sadness, anhedonia, weight loss, sleep disturbance, and psychomotor retardation as a result of the separation in marriage. Other causes are eradicated by the normal levels of thyroid and vitamin D. She has begun taking escitalopram and has already seen some improvement in sleep at an early stage, and meditates. Constant monitoring of the symptoms, medication effects, and the introduction of evidence-based psychotherapy will be encouraged to achieve such a gradual recovery.